 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Neulasta Onpro (pegfilgrastim/onpro) / Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: Neulasta Onpro: a coup de gr (Pubmed Central) - Mar 25, 2023
With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
- ||||| Neulasta Onpro (pegfilgrastim/onpro) / Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Clinical: My vote for coolest slide of #Tandem23: not just outpatient ASCT, but a detailed schema for ASCT at 🏡!! By @LandauHeather @MSKCancerCenter Telemedicine visits, Neulasta Onpro, remote patient monitoring… so many innovations in care over the last decade wrapped into one bundle! (Twitter) - Feb 16, 2023
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis. (Pubmed Central) - May 31, 2022
P=N/A
With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro. Pegfilgrastim OBI was associated with a lower FN incidence in patients with breast cancer compared to other options for FN prophylaxis.
- | Fulphila (pegfilgrastim-jmdb) / Biocon, Viatris, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Journal: Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: Cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. (Pubmed Central) - Oct 1, 2021
Pegfilgrastim (Neulasta), biosimilar pegfilgrastim-jmdb (Fulphila), and pegfilgrastim with on-body injector (OBI; Neulasta Onpro) are options for CIN/FN prophylaxis...Simulations of budget-neutral expanded access to prophylaxis with pegfilgrastim-jmdb or to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL) were also performed...Conversion from pegfilgrastim to pegfilgrastim-jmdb is associated with significant cost-savings which increase markedly when also accounting for pegfilgrastim-OBI failure and associated FN-related hospitalizations. These general and failure-related cost-savings could be allocated on a budget-neutral basis to provide more patients with additional CIN/FN prophylaxis or antineoplastic treatment.
- | Neulasta Onpro (pegfilgrastim/onpro) / Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Journal: Initial testing of pegfilgrastim (Neulasta Onpro) on-body injector in multiple radiological imaging environments. (Pubmed Central) - Jun 22, 2021
Magnetic field changes around an ultrasound system met the limitation set by manufacture. Patient ultrasound scanning is considered safe as long as the transducers do not inadvertently loosen the device.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
[VIRTUAL] Retrospective review of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia () - Dec 26, 2020 - Abstract #ASHP2020ASHP_5023;
The patient’s electronic medical record will be reviewed by the primary investigator for inclusion and exclusion criteria. If the patient meets inclusion criteria, data will be obtained on a collection form and evaluated for appropriateness as documented in current guidelines.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, Udenyca (pegfilgrastim biosimilar) / Coherus
[VIRTUAL] Evaluation of pegfilgrastim products for the primary prophylaxis of febrile neutropenia () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3932;
Purpose: Neulasta, Neulasta Onpro, and the biosimilar UDENYCA are pegfilgrastim products that have been approved by the FDA for the prevention of febrile neutropenia (FN). not applicable
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, Udenyca (pegfilgrastim biosimilar) / Coherus, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Early versus later pegfilgrastim administration on the prevention of chemotherapy-induced febrile neutropenia in patients with high grade B-cell lymphomas receiving R-CHOP-21 () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2594;
The incidence of hospital encounters was not different between the early and later pegfilgrastim administration. FN trended toward a lower incidence in the early group.
- || Clinical, Journal: Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. (Pubmed Central) - Jul 2, 2020
In this simulation, the incremental costs of FN-related hospitalization due to PEG-OBI failure in cycle 1 compared to assured prophylaxis with reference pegfilgrastim, reference filgrastim, and biosimilar filgrastim-sndz varied depending upon the PEG-OBI failure rate and the alternative G-CSF prophylaxis option. Biosimilar filgrastim-sndz offers the greatest cost-efficiency.
- |||| Neulasta Onpro (pegfilgrastim/onpro) / Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Clinical, Reimbursement: Sure, please message me. I think this is a nationwide problem where insurances aren't systematically covering Neulasta OnPro and resulting in patients being exposed to multiple visits in the COVID19 world. (Twitter) - Mar 18, 2020
- | Neulasta Onpro (pegfilgrastim/onpro) / Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Clinical, Journal: Racial Differences in Accepting Pegfilgrastim Onpro Kit (On-Body Injector) Use Among Cancer Patients. (Pubmed Central) - Aug 14, 2019
We believe the current study represents the first look at important racial differences in accepting Onpro kit. Consideration of patients' cultural heritage, race, ethnicity and education may facilitate communication between physicians and patients to achieve optimal cancer care.